Literature DB >> 15662137

RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer.

Lin Zhang1, Nuo Yang, Shun Liang, Andrea Barchetti, Cristina Vezzani, Jia Huang, Ann O'Brien-Jenkins, Stephen C Rubin, George Coukos.   

Abstract

Phosphatidylinositol 3-kinase (PI3-kinase) is a novel intracellular transducer involved in a wide range of cancer-associated signaling pathways, which comprises various isoforms and splice variants with distinct biologic activities and clinical implications. Especially, the class Ia PI3-kinase 110 kD catalytic subunit alpha (PIK3CA) is the most important isoform in tumorigenesis and possibly, tumor angiogenesis. Several strategies have been developed to block PI3-kinase for cancer therapy; however, the approach to target specific PI3-kinase isoform has not been explored to date. In the present study, we show that RNA interference (RNAi) through small interfering (siRNA) sequences targeting PIK3CA has potential applications in isoform-specific "knock-down" of PI3-kinase. This strategy provides a novel tool to study the function of various PI3-kinase isoforms and may contribute to isoform-specific targeting of PI3-kinase in human cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15662137     DOI: 10.4161/cbt.3.12.1388

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  5 in total

1.  Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells.

Authors:  Daizo Yoshida; Kyongson Kim; Masahiro Noha; Akira Teramoto
Journal:  J Neurooncol       Date:  2005-07-30       Impact factor: 4.130

2.  Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities.

Authors:  Amandine Bemmo; Christel Dias; April A N Rose; Caterina Russo; Peter Siegel; Jacek Majewski
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

3.  Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.

Authors:  Ju-yeon Jeong; Kyung-Sul Kim; Ji-Sook Moon; Ji-ae Song; Sung-ho Choi; Kwang-il Kim; Tae-Heon Kim; Hee-Jung An
Journal:  Apoptosis       Date:  2013-04       Impact factor: 4.677

4.  Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment.

Authors:  Nuo Yang; Jia Huang; Joel Greshock; Shun Liang; Andrea Barchetti; Kosei Hasegawa; Sarah Kim; Antonis Giannakakis; Chunsheng Li; Anne O'Brien-Jenkins; Dionyssios Katsaros; Ralf Bützow; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

Review 5.  Modulating the expression of disease genes with RNA-based therapy.

Authors:  Matthew Wood; Haifang Yin; Graham McClorey
Journal:  PLoS Genet       Date:  2007-06       Impact factor: 5.917

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.